The global Injectable Drug Delivery Market, valued at US$633.7 billion in 2024, is forecasted to grow at a robust CAGR of 8.4 ...

Increased 2025 guidance with expected net revenues of $768.0 million to $793.0 million, adjusted non-GAAP EBITDA of $195.0 ...

Zydus Lifesciences on Friday said it has received approval from the US health regulator to market a generic medication.   The ...

Zydus Lifesciences receives USFDA approval to market a generic medication for multiple sclerosis, a generic version of ...

Zydus Lifesciences said that it has has received final approval from the United States Food and Drug Administration (USFDA) for Glatiramer Acetate Injection, 20 mg/mL and 40 mg/mL, single-dose ...

Strong financials, 7% sales growth, Vision 2030 focus, & patient-centric innovation with self-injection solutions ...

In a statement sent to Fierce Pharma Marketing, Cristian Azcarate, argenx’s VP of patient strategy, said the company’s work ...

The desire for patients to have a personalized approach to care is repeated throughout the ad, which was produced by Avalere ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its ...

Dual chamber prefilled syringes market is estimated to be valued at $ 184.7 Mn in 2025, and is expected to reach $ 306.6 Mn by 2032, exhibiting a CAGR of 7.5%. BURLINGAME, CA, UNI ...

Starting in 2025, the Eylea franchise as a whole began to decline due to competitive pressure from long-acting Vabysmo, which competes with Eylea HD, and Pabvlu, a biosimilar version of the original ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull ...